Pregabalin In Partial Seizures Extension Study (PREPS EXT)

Viatris

Status and phase: Completed; Phase 3

Conditions: Seizures

Treatments: Drug: Pregabalin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00143130

A0081015

Details and patient eligibility

About

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

Enrollment: 227 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• met the inclusion/exclusion criteria for A0081005
• have completed the 21-week study and have shown a significant clinical response and wish to continue treatment

Exclusion criteria

• Having a treatable cause of seizure.
• Having a progressive neurological or systemic disorder

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

227 participants in 1 patient group

Single Arm

Experimental group

Treatment:

Drug: Pregabalin